Reuters: Regulatory News: UPDATE 1-BTG vein treatment on track for potential 2014 launch

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-BTG vein treatment on track for potential 2014 launch Apr 12th 2013, 07:20 Fri Apr 12, 2013 3:20am EDT LONDON, April 12 (Reuters) - BTG's Varisolve treatment for varicose veins has been accepted for review by the U.S. Food and Drug Administration, putting it on track for potential approval and launch during the first half of 2014. The speciality pharmaceutical company is relying on the injectable, foam-based treatment to consolidate its transformation from a company that buys up patents and licenses them out into one marketing its own products. BTG, which said on Friday that standard FDA review timelines suggested a decision in the first half of next year, has previously said global sales of Varisolve could reach $500 million a year. Shares in the British group, which also sells snake anti-venom and enjoys royalties from Johnson & Johnson's prostate cancer drug Zytiga, were 1 percent higher by 0715 GMT.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions